-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Regeneron Pharmaceuticals's Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$8.50 B | $16.07 B | $12.17 B | $13.12 B | $14.20 B |
| Cost of Revenue |
|
$1.36 B | $2.72 B | $1.71 B | $2.24 B | $2.45 B |
| Gross Profit |
|
$7.14 B | $13.35 B | $10.47 B | $10.87 B | $11.75 B |
| Research & Development |
|
$2.50 B | $2.62 B | $3.06 B | $3.99 B | $4.62 B |
| Selling,General & Administrative |
|
$1.35 B | $1.82 B | $2.12 B | $2.54 B | $2.90 B |
| Operating Expense |
|
$3.56 B | $4.40 B | $5.08 B | $6.52 B | $7.58 B |
| Operating Income |
|
$3.58 B | $8.95 B | $5.39 B | $4.35 B | $4.17 B |
| Net Income |
|
$3.51 B | $8.08 B | $4.34 B | $3.95 B | $4.41 B |
Regeneron Pharmaceuticals's Assets vs Liabilities & Equity
Regeneron Pharmaceuticals's Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$3.59 B | $5.69 B | $7.74 B | $10.84 B | $9.01 B |
| Inventories |
|
$1.92 B | $1.95 B | $2.40 B | $2.58 B | $3.09 B |
| Total Current Assets |
|
$9.78 B | $14.01 B | $15.88 B | $19.48 B | $18.66 B |
| Property,Plant and Equipment |
|
$3.22 B | $3.48 B | $3.76 B | $4.15 B | $4.60 B |
| Goodwill |
|
- | - | - | - | - |
| Total Assets |
|
$17.16 B | $25.43 B | $29.21 B | $33.08 B | $37.76 B |
| Total Liabilities |
|
$6.14 B | $6.67 B | $6.55 B | $7.11 B | $8.41 B |
| Retained Earnings |
|
$10.89 B | $18.97 B | $23.31 B | $27.26 B | $31.67 B |
| Total Shareholder Equity |
|
$11.03 B | $18.77 B | $22.66 B | $25.97 B | $29.35 B |
| Common Stock |
|
$100.00 K | $100.00 K | $100.00 K | $100.00 K | $100.00 K |
Regeneron Pharmaceuticals's Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$235.90 M | $286.20 M | $341.40 M | $421.00 M | $482.90 M |
| Dividends Payout |
|
- | - | - | - | - |
| Capital Expenditures (Capex) |
|
-$614.60 M | -$551.90 M | -$590.10 M | -$926.40 M | -$755.90 M |
| Free Cash Flow (FCF) |
|
$2.00 B | $6.53 B | $4.42 B | $3.67 B | $3.66 B |
Regeneron Pharmaceuticals's Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$7.14 B | $13.35 B | $10.47 B | $10.87 B | $11.75 B |
| Gross Profit Margin (%) |
|
84.04% | 83.05% | 85.99% | 82.89% | 82.74% |
| Operating Income |
|
$3.58 B | $8.95 B | $5.39 B | $4.35 B | $4.17 B |
| Operating Income Margin (%) |
|
42.09% | 55.67% | 44.24% | 33.15% | 29.39% |
| Net Income |
|
$3.51 B | $8.08 B | $4.34 B | $3.95 B | $4.41 B |
| Net Income Margin (%) |
|
41.35% | 50.25% | 35.64% | 30.14% | 31.07% |
| EBITDA |
|
$4.10 B | $9.67 B | $5.26 B | $4.69 B | $5.32 B |
| EBITDA Margin (%) |
|
48.29% | 60.16% | 43.21% | 35.78% | 37.45% |
Regeneron Pharmaceuticals's Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
31.86% | 43.03% | 19.14% | 15.22% | 15.03% |
| Return on Assets (ROA) |
|
20.47% | 31.75% | 14.85% | 11.95% | 11.69% |
| Debt to Equity |
|
24.45% | 14.38% | 11.92% | 10.41% | 9.21% |
| Debt to total asset |
|
15.71% | 10.61% | 9.25% | 8.17% | 7.16% |
| Enterprise value to revenue |
|
6.18 | 4.14 | 6.31 | 7.14 | 5.43 |
| Enterprise value to EBITDA |
|
12.79 | 6.88 | 14.61 | 19.96 | 14.49 |
| Enterprise value |
|
$52.48 B | $66.57 B | $76.87 B | $93.69 B | $77.08 B |
| Cash to Debt |
|
97.12% | 262.30% | 185.64% | 169.97% | 163.46% |
| Tax Rate (%) |
|
7.80% | 13.41% | 10.71% | 5.85% | 7.68% |
| Payout Ratio |
|
- | - | - | - | - |
Frequently Asked Questions
